Injectable Sustained Release Formulations of Therapeutic Proteins

Cardiff and Langenfeld, April 29th 2010 - Q Chip Ltd and Artes Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C.The study is desgined to evaluate Q-Chips Q-Sphera™ peptideand protein delivery platform to develop a new sustained release microsphere formulation composed of biocompatible polymers loaded with interferon alpha 2a manufactured from ARTES' proprietary yeast Hansenula polymorpha expression system.Q-Sphera™ is a highly enabling bio-encapsulation technology for the development of of polymer based sustained release systems. No harsh solvents or manufacturing conditions are used in the production of the drug (including peptides and proteins) loaded microspheres facilitating benign processing of labile molecules.Hansenula based products, which are already marketed worldwide, are characterized by safety and cost efficiency superior to other microbial technologies. Inteferon alpha 2a manufactured from Hansenula to be better tolerated than the E.coli reference.The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with current marketed pegylated therapies through the development of a month sustained release microsphere formulation. The first phase of the collaboration is expected to be completed by the end of 2010.

Q Chip Ltd - www.q-chip.com
Q Chip is a UK based pharmaceutical company specialising in the development of sustained release peptide and protein therapeutics using its proprietary Q-Sphera™ bioencapsulation platform. In 2004 Q Chip developed the world's first fully-functioning MicroPlant™ platform for the produciton of commercial volumes of uniform, precisely-loaded microcapsules using a wide range of biocompatible polymers. Q Chip encapsulates pharmaceutical drugs into interjectable microspheres for treatment of chronic diseases and cancers. Q Chio is developing two generic drugs, Q-Leuprolide and Q-Octreotide, for cancer treatment.

ARTES Biotechnology GmbH - www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production from yeast expression systems. ARTES offers generation of optimized production cell lines and processes from the proprietary yeast expression systems Hansenula polymorpha and Arxula adeninivorans. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld near Duesseldorf. The company focuses on contract R&D for white and red biotechnology products.

Contacs:
Q Chip Ltd
Dr. Nanette Bartram
Business Development Manager
+44 29 2048 0180

nanette.bartram@q-chip.com

ARTES Biotechnology GmbH
Dr. Melanie Dröttboom
Business Development Director
+ 49 (0)2173 275870
m.droettboom@artes-biotechnology.com